AJANTA PHARMA LTD. - 532331 - Intimation Of Annual General Meeting
Forty-Fourth (44th) Annual General Meeting ('AGM') of the Company will be held on Tuesday, 18th July 2023 at 11.00 a.m. through Video-conference or Other Audio-Visual Means AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 19, 2023 for UMIL Share & Stock Broking Services Ltd AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 19, 2023 for Brij Investments Pvt Ltd AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on May 19, 2023 for Aayush Agrawal, trustee Aayush Agrawal Trust
Buy Ajanta Pharma; target of Rs 1700: YES Securities
YES Securities is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 1700 in its research report dated May 08, 2023. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Further to our communication dated 5th May 2023 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, written transcript of the earnings call held on 5th May 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link https://ajantapharma.com//images/EarningsCallTranscriptQ4(Jan-Mar)2022-23.pdf. AJANTA PHARMA LTD. - 532331 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to the above, please find enclosed herewith the copy of the Annual Secretarial Compliance Report for year ended 31st March 2023 issued by M/s. Alwyn Dsouza & Co., Practicing Company Secretaries pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements), 2015. This is for your information and record.
Buy Ajanta Pharma; target of Rs 1490: Motilal Oswal
Motilal Oswal is bullish on Ajanta Pharma recommended buy rating on the stock with a target price of Rs 1490 in its research report dated May 06, 2023. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter and year ended 31st March 2023 published in the following newspapers on 6th May 2023: 1. Mumbai edition of Business Standard and 2. Mumbai edition of Navakal. This is for your information and record. AJANTA PHARMA LTD. - 532331 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the earnings call held on 5th May 2023 at 4.00 p.m. has been uploaded on the Company's website and can be accessed through the link: https://ajantapharma.com//images/EAC-Q4-(Jan-Mar)-2022-23.mp3 Written transcript of the same will be submitted in due course. This is for your information and records please.